The FDA grants Stemline Therapeutics' (STML-0.1%) SL-401 compound Orphan Drug designation for the treatment of a rare and aggressive blood cancer called blastic plasmacytoid dendritic cell neoplasm, for which there is no effective treatment. The decision adds to SL-401's also Orphan Drug status for acute myeloid leukemia. (PR)